Ken Griffin 2seventy Bio, Inc. Put Options Transaction History

Citadel Advisors LLC

8 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q3 2024 Nov 14, 2024	SELL	$3.85 - $5.05 $18,865 - $24,745	-4,900 Reduced 50.52%	4,800 $22,000
Q2 2024 Aug 14, 2024	SELL	$3.6 - $5.79 $66,600 - $107,115	-18,500 Reduced 65.6%	9,700 $37,000
Q1 2024 May 15, 2024	SELL	$3.09 - $6.0 $81,576 - $158,400	-26,400 Reduced 48.35%	28,200 $150,000
Q4 2023 Feb 14, 2024	BUY	$1.57 - $4.58 $49,455 - $144,270	31,500 Added 136.36%	54,600 $233,000
Q3 2023 Nov 14, 2023	BUY	$3.14 - $11.2 $65,312 - $232,959	20,800 Added 904.35%	23,100 $90,000
Q2 2023 Aug 14, 2023	SELL	$8.45 - $12.48 $21,125 - $31,200	-2,500 Reduced 52.08%	2,300 $23,000
Q1 2023 May 15, 2023	SELL	$9.21 - $14.98 $76,111 - $123,794	-8,264 Reduced 63.26%	4,800 $48,000
Q4 2022 Feb 14, 2023	BUY	$8.57 - $17.0 $111,958 - $222,088	13,064 New	13,064 $122,000

126

45.6M

122K

19.8K

Ticker TSVT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 37,873,600
Market Cap $113M
Description
2seventy bio, Inc., a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. Its products pipeline includes idecabtagene vicleucel; ide-cel or Abecma and bb21217; and CAR-T cell product candidates for the treatment of multiple myeloma. 2seventy bio, Inc. has a col...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.